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A new family of “FeII(5-C5H5)” half sandwich compounds bearing a N-heteroaromatic ligand 41 
coordinated to the iron center by a nitrile functional group has been synthesized and fully characterized 42 
by NMR and UVeVis spectroscopy. X-ray analysis of single crystal was achieved for complexes 1 and 43 
3, which crystallized in the monoclinic P21/c and monoclinic P21/n space groups, respectively. Studies 44 
of interaction of these five new complexes with plasmid pBR322 DNA by atomic force microscopy 45 
showed very strong and different types of interaction. Antiproliferative tests were examined on human 46 
leukemia cancer cells (HL-60) using the MTT assay, and the IC50 values revealed excellent 47 





Organometallic chemistry emerged in the recent years as an 51 
attractive field for the search of new compounds as potential drugs 52 
for medicinal chemistry, in particular for chemotherapy. In this 53 
frame, metallocene derivatives have appeared at the end of the 54 
1970s with the pioneering work of Köpf and Köpf-Maier involving 55 
the antitumor activity of early transition-metal cyclopentadienyl 56 
complexes [1]. The promising results obtained for dichloride metallocenes 57 
(Cp2MCl2, where M = Ti, V, Nb, Mo; Cp = 5-cyclopentadienyl) 58 
showing antitumor activity against numerous tumors, 59 
such as Ehrlich ascites tumor, B16 melanoma, colon 38 carcinoma 60 
and Lewis lung carcinoma, as well as against several human tumors 61 
heterotransplanted to athymic mice, certainly constitute an 62 
important impulsion for the interest of this area [2]. Titanium 63 
dichloride, (5-C5H5)2TiCl2, was the first of such species in clinical 64 
trials [3]. Nevertheless, problems related with formulation led to 65 
the abandonment of titanocene dichloride in Phase II clinical trials 66 
[4 -6]. Ferrocene derivatives also appeared with promising results 67 
showing activity against Rauscher leukemia virus and EAT in CF1 68 
mice [7,8] and in P388 leukemia cells [9] reinoculated tumors [10]. 69 
Particularly, the ferrocifens family, which is a ferrocene derivative 70 
of tamoxifen (Astra Zeneca, London, UK e the drug used for treating 71 
breast cancer), has revealed good cytotoxicity activities. However, 72 
these molecules suffer from poor bioavailability restricting them 73 
from entering clinical trials. In order to overcome this limitation 74 
and advance toward clinical studies, several formulations are being 75 







The half-sandwich family of compounds emerged more recently 81 
using different central metals and has revealed potentialities as 82 
anticancer drugs. The particular geometry of piano stool compounds 83 
provides a good scaffold for building new molecules by 84 




chelated active ligand and also the coligands. In this context, 89 
[Ru(6-arene)(X)(Y-Z)] complexes (where Y-Z is a chelating 90 
ligand, and X is monoanionic ligand) revealed high cytotoxicity 91 
against human ovarian tumor cells [12 -15] and they are thought to 92 
act through covalent Ru-DNA interactions [16,17]. Related compounds 93 
incorporating the 1,3,5-triaza-7-phosphaadamantane 94 
(PTA) ligand, such as [Ru(6-p-cymene)(PTA)Cl2] (RAPTA-C), have 95 
shown activity against metastases and although their mechanism 96 
of action has not been established, a pH dependent interaction with 97 
DNA may be a key component [18]. During the last years, our 98 
research group has been exploring a third family of half-sandwich 99 
compounds based on the “RuII(5-C5H5)” fragment, with the general 100 
formula [Ru(5-Cp)(P-P)(L)][X] (where P-P is a chelating 101 
phosphane or two phosphane ligands, L is a N-heteroaromatic 102 
sigma ligand mono or bidentate ligand and X is a counterion) [19 - 103 
24]. Our studies showed significant toxicity for a variety of cancer 104 
cell lines, namely LoVo and HT29 human colon adenocarcinoma, 105 
MiaPaCa pancreatic cancer cell lines, HL-60 human leukemia cancer 106 
cells, A2780 human ovarian cancer cells (and the resistant form 107 
A2780CisR), MCF7 and MDAMB231 human breast cancer cells 108 
(estrogen dependent and independent, respectively) and PC3 human 109 
prostate cancer cells, with IC50 values lower than those of 110 
cisplatin in most cases [19 -24]. One important advantage of 111 
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ruthenium based compounds for therapeutic uses compared to 112 
other metal complexes, is pointed out on its ability to mimic iron in 113 
binding biologically relevant molecules such as albumin and 114 
transferrin and consequently to show much lower toxicity than 115 
that of platinum therapies [25]. The success of the coordination of 116 
N-heteroaromatic ligands to the fragment ‘RuCp’ in terms of finding 117 
new compounds with important cytotoxicity against several cancer 118 
cell lines led us to extend our studies to the analog ‘FeCp’ derivatives. 119 
In this context, we have recently published our first results 120 
concerning a new family of compounds with the general 121 
cationic structure [Fe(5-Cp)(P-P)(L)] +, where L is coordinated to 122 
the iron center by the N atom of the heteroaromatic ligand [26]. 123 
These new compounds showed values of cytotoxicity against MCF7 124 






Having in mind to exploit the effect of cytotoxicity of other 131 
ligands coordinated by a different group than a N-heteroaromatic 132 
atom, we had previously studied two new [Ru(5- 133 
Cp)(PPh3)2(N ≡ CL)]+ derived compounds where N ≡ CL was coordinated 134 
by a nitrile functional group (benzo[1,2-b; 4,3-b’] 135 
dithio-phen-2-carbonitrile and [5-(2-thiophen-2-yl)-vinyl]-thiophene- 136 
2-carbonitrile]) which were tested against HL-60 cells 137 
[20]. The IC50 values obtained after 24 h of incubation were 138 
1.46 ± 0.25 and 5.89 ± 0.67 mM, respectively, while cisplatin in 139 
the same experimental conditions presented a higher IC50 value 140 
of 15.61 ± 1.15 mM. These motivating results obtained with 141 
ruthenium coordinated nitrile ligands together with our interest 142 
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to continue the exploitation of the cytotoxic properties of ‘FeCp’ 143 
compounds led us to the synthesis of a new family of iron nitrile 144 
compounds of general formula [Fe(5-Cp)(NCL)(P-P)]+. In the 145 
present paper we report the synthesis of compounds of the 146 
general formula [Fe(5-Cp)(NCL)(P-P)] +, where the NCL ligands, 147 
2-quinolinecarbonitrile (L1), 3-quinolinecarbonitrile (L2), 2- 148 
pyrazinecarbonitrile (L3) or 2,3-pyrazinedicarbonitrile (L4), present 149 
on their structures one or two N-heteroaromatic rings. These 150 
new compounds were fully characterized and their interaction 151 
with plasmid pBR322 DNA was studied by atomic force microscopy. 152 
Moreover, their potentialities as cytotoxic agents against 153 
human leukemia cancer cells (HL-60 cells) were evaluated. 154 
Remarkably, our studied compounds revealed IC50 values lower 155 
than those of cisplatin. Apoptotic behavior was also evaluated 156 




2.1. General procedures 161 
All syntheses were carried out under dinitrogen atmosphere using current Schlenk techniques and the 162 
solvents used were dried using standard methods [27]. [Fe(5-C5H5)(dppe)I] was prepared following 163 
the method described in literature [28]. FT-IR spectra were recorded in a Mattson Satellite FTIR 164 
spectrophotometer with KBr pellets; only significant bands are cited in text. 1H, 13C and 31P NMR 165 
spectra were recorded on a Bruker Avance 400 spectrometer at probe temperature. The 1H and 13C 166 
chemical shifts are reported in parts per million (ppm) downfield from internal Me4Si and the 31P NMR 167 
spectra are reported in ppm downfield from external standard, 85% H3PO4. Elemental analyses were 168 
obtained at Centro de Apoio Científico Tecnológico Á Investigación (C.A.C.T.I.), at Universidade de 169 
Vigo, using a Fisons Instruments EA1108 system. Electronic spectra were recorded at room temperature 170 
on a Jasco V-560 spectrometer in the range of 200-900 nm. 171 
 172 
2.2. Complexes synthesis 173 
2.2.1. General procedure applied to the synthesis of the complexes 1-5 174 
To a stirred suspension of 0.5 mmol of [FeCp(dppe)I] in dichloromethane (25 mL) was added 0.6 mmol 175 
of the adequate ligand (L1 = 2-quinolinecarbonitrile; L2 = 3-quinolinecarbonitrile; L3 ¼ 2-176 
pyrazinecarbonitrile; L4 = 2,3-pyrazinedicarbonitrile) followed by addition of 0.6 mmol of TlPF6 (for 177 
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complexes 1, 2, 3 and 4) or AgCF3SO3 (for complex 3). After refluxing for a period of 5-6 h the color 178 
changed from gray to orange reddish. The reaction mixture was cooled down to room temperature and 179 
the solution was filtered to eliminate the TlCl or the AgCl precipitate. The solvent was then removed 180 
under vacuum and the residue was washed with n-hexane (2 x 10 mL). Dark red crystals were obtained 181 
after recrystalization from dichloromethane/n-hexane solutions. 182 
Compound 5 was obtained by stirring for 90 min, a suspension of 0.32 g (0.5 mmol) of [FeCp(dppe)I] 183 
and TlPF6 (0.21 g, 0.6 mmol), in dichloromethane (25 mL) to which a solution of 2,3-dicianopyrazine 184 
in dichloromethane (0.078 g; 0.6 mmol) was slowly added. The obtained purple solution was dried and 185 
washed with n-hexane, giving a powder, which after recrystalization from dichloromethane/n-hexane, 186 
gave needle shaped purple crystals. 187 
 188 
2.2.2. [FeCp(dppe)(2-cq)][PF6], 1  189 
Dark red; Yield = 81%. IR (KBr, cm-1): (C ≡ N, stretch) 2208, (PF6) 837 and 557. 1H NMR 190 
((CD3)2CO, Me4Si, /ppm): 8.30 (d, 1, H10); 8.15 (t, 4, dppe); 7.96 (dd, 2, H4 þ H7); 7.88 (t, 1, H6); 191 
7.73 (t, 1, H5); 7.53 (m,16, dppe); 6.78 (d,1, H9) 4.75 (s, 5, h5-C5H5); 2.80 (m, 4, CH2-dppe). 13C NMR 192 
((CD3)2CO, Me4Si, /ppm): 148.3 (C8); 138.0 (C9); 137.6-137.0 (Cq, dppe); 133.8 (CH-, dppe); 133.1 193 
(C ≡ N); 132.5 (CH-, dppe); 132.2 (C6); 131.6-131.4 (CH-, dppe); 130.3 (C5); 130.0 (C4); 129.9 (CH-, 194 
dppe + C3); 129.4 (C2); 128.9 (C7); 123.8 (C10); 81.4 (Cp); 28.4 (-CH2-, dppe). 31P((CD3)2CO, d/ppm): 195 
96.2 (s, dppe); -144.2 (setp, PF6). UV-Vis. in CH2Cl2, max/nm (ε/M-1 cm-1): 240 (73,195), 385 (6049), 196 
441 (6893). UV-Vis. In DMSO, max/nm (ε/M-1 cm-1): 392 (Sh), 455 (7669). Elemental analysis (%) 197 
Found: C, 59.50; H, 4.30; N, 3.40; Calc. for C41H35N2P3F6Fe ꞏ 0.1CH2Cl2 (826.9): C, 59.70.16; H, 198 
4.30; N, 3.40.  199 
 200 
2.2.3. [FeCp(dppe)(3-cq)][PF6], 2 201 
Dark red; Yield: 80%. IR (KBr, cm-1): (C ≡ N, stretch) 2210, (PF6) 837 and 557. 1H RMN 202 
((CD3)2CO, Me4Si, /ppm): 8.15 (t, 4, C6H5-dppe); 8.00 (d, 1, H5); 7.92 (m, 2, H3 + H7); 7.85 (d, 1, 203 
H8); 7.71 (t, 1, H6); 7.68 (s, 1, H10); 7.58 (m, 16, C6H5-dppe); 4.73 (s, 5, 5-C5H5); 2.82 (m, 4, CH2). 204 
13C NMR ((CD3)2CO, Me4Si, /ppm): 149.9 (C3); 148.8 (C2); 142.3 (C10); 137.7 - 137.1 (Cq, dppe); 205 
134.0 (CH-, dppe); 133.8 (C7); 132.4 (CH-, dppe); 131.7 - 131.4 (CH-, dppe); 130.1 (C5); 130.0 (CH-, 206 
dppe); 129.4 (C8); 129.3 (C6); 126.5 (C4); 107.1 (C9); 81.1 (Cp); 28.5 (-CH2-, dppe); C1 is overlapped 207 
by dppe signals. 31P RMN ((CD3)2CO, /ppm): 97.1 (s, dppe); -144.2 (setp, PF6). UV - Vis in CH2Cl2, 208 
max/nm (ε/M-1 cm-1): 239 (75,639), 376 (7169), 429 (5136). UV - Vis in DMSO, max/nm (ε/M-1 cm-209 
1): 386 (6559), 442 (7292). Elemental analysis (%) Found: C, 59.10; H, 4.30; N, 3.40; C41H35N2P3F6Fe 210 







2.2.4. [FeCp(dppe)(3-cq)][CF3 SO3], 3 216 
Dark red; Yield: 80%. IR (KBr, cm-1): n(C ≡ N, stretch) 2212, (CF3SO3) 1269. 1H NMR ((CD3)2CO, 217 
Me4Si, /ppm): 8.15 (t, 4, C6H5-dppe); 8.01 (d, 1, H5); 7.92 (m, 2, H3 + H7); 7.87 (d, 1, H8); 7.71 (m, 218 
2, H10 + H6); 7.63 (t, 4, C6H5-dppe); 7.57 (m, 12, C6H5-dppe); 4.74 (s, 5, 5-C5H5); 2.80 (m, 4, CH2). 219 
13C NMR ((CD3)2CO, Me4Si, /ppm): 149.7 (C3); 148.6 (C2); 142.6 (C10); 137.7 -137.4 (Cq, dppe); 220 
134.0 (CH-, dppe); 133.8 (C7); 132.4 (CH-, dppe); 132.1 (C1); 131.7 - 131.4 (CH-, dppe); 130.2 (C5); 221 
130.0 (CH-, dppe); 129.4 (C8); 129.3 (C6); 126.6 (C4); 107.1 (C9); 81.1 (Cp); 28.5 (-CH2-, dppe). 31P 222 
RMN (CD3Cl3, /ppm): 97.1 (s, dppe). UV - Vis in CH2Cl2, max/nm (ε/M-1 cm-1): 239 (51,562), 369 223 
(3559), 428 (2371). UV - Vis in DMSO, max/nm (ε/M-1 cm-1): 386 (4380), 442 (4798). Elemental 224 
analysis (%) Found: C, 57.4; H 4.2; N, 3.08; C42H37N2P2F3SO3-Fe ꞏ CH2Cl2: C, 56.8; H, 4.32; N, 3.08. 225 
 226 
2.2.5. [FeCp(dppe)(cpz)][PF6], 4 227 
Red; Yield: 85%. IR (KBr, cm-1): n(C≡N, stretch) 2218, (PF6) 837 and 557. 1H NMR ((CD3)2CO, 228 
Me4Si, /ppm) 8.67 (d, 1, H4); 8.55 (d, 1, H5), 8.05 (m, 4, C6H5), 7.88 (s, 1, H3), 7.56 - 7.48 (m, 16, 229 
C6H5), 4.75 (s, 5, 5-C5H5); 2.79 (m, 4, CH2). 13C NMR ((CD3)2CO, Me4Si, /ppm): 148.9 (C3), 147.8 230 
(C4), 146.2 (C5), 137.4 - 137.0 (Cq, dppe); 133.8 (CH-, dppe); 132.5 (CH-, dppe); 131.5 (CH-, dppe); 231 
130.0 (CH-, dppe); 81.7 (Cp); 28.4 (-CH2-, dppe).31P NMR ((CD3)2CO, /ppm): 96.10 (s, dppe); -144.2 232 
(setp, PF6). UV-Vis in CH2Cl2, max/nm (ε/M-1 cm-1): 264 (20,282), 388 (2564), 445 (2895). UV-Vis 233 
in DMSO, max/nm (ε/M-1 cm-1): 446 (5225). Elemental analysis (%) Found: C, 55.75; H, 4.1; N, 5.35; 234 
Calc. for C36H32N3P3F6Fe ꞏ 1/10CH2Cl2: C, 55.74; H, 4.17; N, 5.40. 235 
 236 
2.2.6. [FeCp(dppe)(2,3-dcpz)][PF6], 5 237 
Purple; yield: 86%. IR (KBr, cm-1): n(C≡N, stretch) 2198, n(PF6) 837 and 559. 1H RMN (CDCl3, 238 
Me4Si, /ppm): 8.84-8.81 (m, 2, H4 + H5); 8.00 (t, 4, C6H5); 7.48 (m, 16, C6H5); 4.86 (s, 5, 5-C5H5); 239 
2.85 (m, 4, CH2). 13C NMR ((CD3)2CO, Me4Si, /ppm): 148.8 (C4); 147.0 (C5); 137.1-136.6 (Cq, 240 
dppe); 133.8 (CH-, dppe); 133.2 (C2 + C3); 131.7 (CH-, dppe); 130.1 (CH-, dppe); 120.0 (CH-, dppe); 241 
128.7 (C1); 114.6 (C6); 82.7 (Cp); 28.6 (-CH2-, dppe). 31P RMN ((CD3)2CO, /ppm): 95.4 (s, dppe); -242 
144.27 (setp, PF6). UV- Vis in CH2Cl2, max/nm (ε/M-1 cm-1): 266 (12,201), 521 (2521). UV-Vis in 243 
DMSO, max/nm (ε/M-1 cm-1): 512 (5710). Elemental analysis (%) Found: C, 55.10; H, 4.0; N, 6.90; 244 
Calc. for C41H35N2P3F6Fe ꞏ 0.2CH2Cl2 (811.40): C, 55.94; H, 3.93; N, 7.05.  245 
 246 
2.3. Crystal structure determination of [FeCp(dppe)(2-cq)][PF6] 1 and [FeCp(dppe)(3-cq)][CF3SO3] 247 
3 248 
Prismatic crystals (0.1 x 0.1 x 0.2 mm and 0.2 x 0.1 x 0.1 mm respectively) were selected and mounted 249 
on a MAR345 diffractometer with an image plate detector. Intensities were collected with graphite 250 
monochromatized Mo K radiation. Lorentzpolarization and absorption corrections were made. The 251 
structures were solved by Direct methods, using SHELXS computer program [29] and refined by full-252 
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matrix least-squares method with SHELX93 computer program [30], (very negative intensities were not 253 
assumed). The function minimized was w||Fo|2 - |Fc|2|2, where  = [2(I) + (0.0566P)2 + 0.4472P]-1, 254 
and P = (|Fo|2 + 2|Fc|2)/ 3, f, f’ and f” were taken from International Tables of X-Ray Crystallography 255 
[31]. All H atoms were located from a difference synthesis and refined with an overall isotropic 256 
temperature factor. CCDC 939633 and 939634 contain the supplementary crystallographic data for this 257 
paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via 258 
www. ccdc.cam.ac.uk/data_request/cif. 259 
 260 
2.4. Electrochemical experiments 261 
The electrochemical experiments were performed on an EG&G Princeton Applied Research Model 262 
273A potentiostat/galvanostat and monitored with a personal computer loaded with Electrochemistry 263 
PowerSuite v2.51 software from Princeton Applied Research. Cyclic voltammograms were obtained in 264 
0.1 M or 0.2 M solutions of [NBu4][PF6] in CH3CN or CH2Cl2 respectively, using a three-electrode 265 
configuration cell with a platinum-disk working electrode (1.0 mm diameter) probed by a Luggin 266 
capillary connected to a silver-wire pseudo-reference electrode and a Pt wire counter electrode. The 267 
electrochemical experiments were performed under a dinitrogen atmosphere at room temperature. The 268 
redox potentials were measured in the presence of ferrocene as the internal standard and the redox 269 
potential values are normally quoted relative to the SCE by using the ferrocenium/ferrocene redox 270 
couple (E1/2 = 0.46 or 0.40 V vs. SCE for CH2Cl2 or CH3CN, respectively) [32]. The supporting 271 
electrolyte was purchased from Fluka, electrochemical grade was dried under vacuum for several hours 272 
and used without further purification. Reagent grade acetonitrile and dichloromethane were dried over 273 
P2O5 and CaH2, respectively, and distilled under dinitrogen atmosphere before use. 274 
 275 
2.5. DNA interaction studies 276 
2.5.1. Formation of drugeDNA complexes 277 
Deionized Milli-Q water (18.2 M) was filtered through 0.2-nm FP030/3 filters (Schleicher & Schuell) 278 
and centrifuged at 4.000 g prior to use. pBR322 DNA was heated at 60 °C for 10 min to obtain open 279 
circular (OC) form. To stock aqueous solutions of plasmid pBR322 DNA in Hepes buffer (4 mM Hepes, 280 
pH 7.4/2 mM MgCl2) were added aqueous solutions (with 4% of DMSO) of complexes 1-5 in a 281 
relationship DNA base pair to complex 10:1. In parallel experiments, blank sample of free DNA and 282 
DNA complex solutions were equilibrated at 37 °C for 4 h in the dark shortly thereafter. 283 
 284 
2.5.2. AFM imaging 285 
Atomic force microscopy (AFM) samples were prepared by casting a 3-L drop of test solution onto 286 
freshly cleaved green mica disks as support. The drop was allowed to stand undisturbed for 3 min to 287 
favor the adsorbate-substrate interaction. Each DNA-laden disk was rinsed with Milli-Q water and was 288 
blown dry with clean compressed argon gas directed normal to the disk surface. Samples were stored 289 
over silica prior to AFM imaging. All AFM observations were made with a Nanoscope III Multimode 290 
AFM (Digital Instrumentals, Santa Barbara, CA). Nano-crystalline Si cantilevers of 125-nm length with 291 
a spring constant of 50 N/m average ended with conical-shaped Si probe tips of 10-nm apical radius and 292 
cone angle of 35° were used. High-resolution topographic AFM images were performed in air at room 293 
temperature (relative humidity < 40%) on different specimen areas of 2 x 2 mm operating in intermittent 294 
contact mode at a rate of 1-3 Hz. 295 
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2.6. Growth inhibition assays 296 
Antiproliferative activity of these new iron complexes, and cisplatin, was tested in a cell culture system 297 
using the human acute promyelocytic leukemia cell line HL-60 (American Type Culture Collection 298 
(ATCC)). The cells were grown in RPMI-1640 medium supplemented with 10% (v/v) heat inactivated 299 
fetal bovine serum, 2 mmol/L glutamine (Invitrogen, Inc.) in a highly humidified atmosphere of 95% 300 
air with 5% CO2 at 37 °C. Growth inhibitory effect was measured by the microculture tetrazolium [3-301 
(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT assay [33]. Cells were seeded at 302 
density 104 cells/well in 100 mL of culture medium and after that cells were treated with different 303 
concentrations ranging from 0 (culture medium) to 200 M of compounds in 100 l of culture medium. 304 
The exact concentrations assayed were 0.1, 0.24, 0.5, 0.75, 1, 2.5, 5, 10, 25, 50, 100 and 200 M. All 305 
the assays were done in quadruplicate and three independent assays were realized. After incubation at 306 
37 °C during 24 h or 72 h, without washing, 20 l of soluble tetrazolium salt was added to each well 307 
and incubated 3 additional hours. As we used soluble tretrazolium salts we determined the amount of 308 
formazan directly reading the absorbance at 490 nm in a spectrophotometric plate reader (Labsystems 309 
iEMS Reader MF). Cytotoxicity was evaluated in terms of cell growth inhibition in treated cultures 310 
versus that in untreated controls. IC50, the concentration of compound at which cell proliferationwas 311 
50% of that observed in control cultures, were obtained by GraphPad Prism software, version 4.0. 312 
Experiments were repeated at least three times to get the mean values.  313 
 314 
 315 
2.7. Apoptosis assays 316 
Induction of apoptosis in vitro by iron compounds was determined by a flow cytometric assay with 317 
Annexin V-FITC by usingan Annexin V-FITC Apoptosis Detection Kit (Roche) [34]. Exponentially 318 
growing HL-60 cells in 6-well plates (5 x 105 cells/well) were exposed to concentrations equal to the 319 
IC50 of the platinum and iron drugs for 24 h. After, the cells were subjected to staining with the Annexin 320 





3. Results and discussion 324 
 325 
3.1. Synthesis of Fe(II) complexes 326 
Five new cationic iron(II) complexes (1e5) of the general type [Fe(5-C5H5)(dppe)L][X] where L = 2-327 
quinolinecarbonitrile (L1), 3-quinolinecarbonitrile (L2), 2-pyrazinecarbonitrile (L3) or 2,3-328 
pyrazinedicarbonitrile (L4) and X = PF6 or CF3SO3 were prepared by  coordination of the functional 329 
nitrile N≡C group of the L1-L4 ligands (Scheme 1). Compounds were obtained in good yields (80-86%), 330 
by halide abstraction from [Fe(5-C5H5)(dppe)I] with thallium hexafluorophosphate or silver triflate, in 331 
dichloromethane, in the presence of a slight excess of the adequate ligand and recrystallized from 332 
dichloromethane/n-hexane solutions. The new compounds are stable in cellular media for several hours 333 
(Fig. S1, in SI) and were all fully characterized by FT-IR, 1H, 13C and 31P NMR spectroscopies; the 334 
elemental analyses were in accordance with the proposed formulations. The structures of compounds 1 335 
and 3 were also characterized by X-ray diffraction studies (see below).  336 
Solid state FT-IR spectra (KBr pellets) of the complexes present the characteristic bands of the 337 
cyclopentadienyl ligand (≈3050 cm-1), the PF6 (840 and 550 cm-1) or CF3SO3 (1250 cm-1) anion and 338 
the characteristic stretching vibration of the nitrile functional group in the range 2200e2220 cm-1. The 339 
coordination of the ligand to the metal center lead to a weakness of the N≡C of -20 cm-1 for compounds 340 
1-4 being this value somehow higher (-47 cm-1) for compound 5, probably due to the presence of the 341 
second nitrile acceptor group. These negative shifts observed on N≡C are in good agreement with the 342 
values found before for other related 5-monocyclopentadieny iron compounds [35-37] and show an 343 
enhanced -backdonation from the metal d orbitals to the * orbital of the N≡C group leading to a 344 
decreased N≡C bond order. 345 
1H NMR chemical shifts of the cyclopentadienyl ring are displayed in the characteristic range of 346 
monocationic iron(II) complexes (4.70-4.90 ppm, Table 1). The effect of coordination on the nitrile 347 
ligands is observed through the shielding of the ortho protons relatively to N≡C coordination position 348 
(≈1.20 ppm) in compounds 2-4 indicating an electronic flow towards the heteroaromatic ligand due to 349 
-backdonation involving the metal center. Furthermore, an increased electronic density was also found 350 
in compound 1 in both ortho (≈0.30 ppm) and meta (≈1.20 ppm) protons with special relevance for the 351 
meta position (opposite to N in the heteroaroamtic ring) probably due to a higher contribution of the 352 
corresponding resonance form. The electronic flow in compound 1 is still observed in the second fused 353 
ring (≈0.20 ppm). This shielding effect on the second fused ring was also observed for compounds 2 354 
and 3. Here, the difference in the anion did not cause any additional effect. Relatively to the 355 
pyrazinecarbonitrile complexes (4 and 5) both protons suffered a shielding of about 0.30 ppm. 13C NMR 356 
data confirm the evidence found for proton spectra. The Cp ring chemical shifts are in the range usually 357 
observed for Fe(II) cationic derivatives, a significant deshielding (up to ≈14 ppm) being observed on 358 
the carbon of the N≡C functional group upon coordination. All the other carbons of the chromophore 359 
ligand were only slightly deshielded or remained almost unchanged for the studied compounds. 31P 360 
NMR data of the complexes showed the typical septuplet of the PF6 anion at approximately - 144 ppm 361 
(with the exception of compound 3 where the PF6 anion was replaced by CF3SO3). Moreover, a single 362 
sharp signal corresponding to the phosphine coligand (≈96 ppm) was observed for all the complexes, 363 
revealing the equivalency of the two phosphorus atoms, together with the expected deshielding upon 364 
coordination, in accordance with its  donor character. Table 1 displays the 1H NMR chemical shifts of 365 
the ligands (L1-L4) and corresponding complexes (1-5) in (CD3)2CO. 366 
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3.2. UV-Vis studies 367 
The optical absorption spectra of these five new Fe(II) complexes and all the ligands were recorded in 368 
10-3-10-5M dichloromethane solutions in order to identify any MLCT absorption and -* absorption 369 
bands expected for these complexes (Table 2). The electronic spectra of all the compounds showed 370 
intense absorption bands in the UV region, which can be assigned to electronic transitions occurring 371 
both in the organometallic fragment {FeCp(dppe)}+ ( ≈ 235-260 nm) and in the coordinated 372 
chromophore ( ≈ 260-450 nm) (Fig. 1). Additional charge transfer (CT) bands were also observed in 373 
all studied complexes. In fact, all complexes presented one band compatible with a MLCT nature, which 374 
was confirmed by solvatochromism studies in DMSO (example given in Fig. 2 for complex 1). 375 
 376 
3.3. X-ray structural studies of the complexes [Fe(5-C5H5)(dppe)(2-cq)][PF6] 1 and [Fe(5-377 
C5H5)(dppe)(3-cq)][CF3SO3] 3 378 
Suitable crystals for X-ray diffraction studies of the complexes [Fe(5-C5H5)(dppe)(2-cq)][PF6] 1 and 379 
[Fe(5-C5H5)(dppe)(3-cq)] [CF3SO3] 3, crystallized in different crystalline systems and space groups 380 
(monoclinic P21/c and monoclinic P21/n space groups, respectively). Crystal data and structure 381 
refinement for both complexes are collected in Table 3. In Fig. 3 and Fig. 4 the molecular structure of 382 
both complexes 1 and 3 are respectively presented. Both complexes present the usual distorted three-383 
legged piano stool geometry for 5-monocyclopentadienyl complexes confirmed by P-Fe-P angles of 384 
86.93e87.11° and N-Fe-P angles varying from 90.02 to 92.64°, with the remaining 5-Cp(centroid)-Fe-385 
X (with X = N or P) angles between 120.40 and 128.39° (see Table 4). These values are within the range 386 
found for 5-monocyclopentadienylmetal nitrile derivatives with coordinated phosphanes. [38-40] The 387 
distances Fe-5-Cp(centroid) are very similar in both complexes (1.7153 Å for complex 1, and 1.7164 388 
Å for complex 3) and in good agreement with the donor/acceptor nature and number of other ligands 389 
bound to iron atom. The distances Fe-N≡C range from 1.8670 to 1.8865Å are well within the values 390 
expected for this family of compounds and their bond angles present only a slight deviation of the 391 
linearity, with values in accordance to those found for related compounds [38-40]. Different spatial 392 
orientation of the two isomeric ligands in both complexes can be observed. This fact can have some 393 
biological importance since it might determine the way of interaction of each complex with DNA or 394 
other biological molecules. In Table 4, the main bond lengths and angles are presented. 395 
 396 
3.4. Electrochemical studies 397 
In order to obtain an insight on the electron richness of the organometallic fragment and on the 398 
coordinated ligands, the electrochemical properties of the ligands L1-L4 and the new iron(II) complexes 399 
were studied by cyclic voltammetry in acetonitrile and dichloromethane solutions (1 x 10-3 M) using 400 
0.1 M or 0.2 M tetrabutylammonium hexafluorophosphate (TBAPF6) as supporting electrolyte, between 401 
the limits imposed by the solvents. The electrochemical data measured for the studied compounds at the 402 
scan rate of 0.200 V/s, are reported in Table 5 and Table 6. The redox behavior of the ligands L1-L3 403 
was characterized by an irreversible reductive process near -1.70 V, whereas for the 2,3-404 
pyrazinedicarbonitrile ligand (L4) this process is observed at -1.15 V, for both solvents. The 405 
electrochemical responses of the iron(II) compounds 1, 2, 4 and 5 in acetonitrile were characterized by 406 
the presence of an irreversible redox process in the positive potential range and two or three reductive 407 
processes at negative potentials. This behavior is also expected for compound 3 since its cation is 408 
isostructural of compound 2. The cyclic voltammogram of complex [FeCp(dppe)(2,3-dcpz)][PF6] 5 is 409 
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showed on Fig. 5 and typifies the behavior found for all the complexes in this solvent. The irreversible 410 
oxidation placed in the range 0.80e0.92 V can be attributed to the metal centered process (FeII/FeIII). 411 
The correspondent reductive wave was observed at 0.62 V for all the complexes and no changes in this 412 
potential were observed at different scan rates. This behavior can be related with an FeII  FeIII 413 
oxidation, leading to the 17-electron species [FeCp(dppe)(L)]2+, formed on the electrode surface which 414 
undergo fast substitution of the cyanoquinoline or pyrazine ligands by an acetonitrile molecule. The 415 
formed [FeCp(dppe)(NCCH3)]+ species is responsible for the observed reductive process when the scan 416 
direction is reverted. Moreover, the presence of a small reductive wave in the free ligand position (Epc 417 
= -.16 V) (Fig. 5) confirms the ligand exchange process. This result is consistent with the redox behavior 418 
of the isolated complex [FeCp(dppe)(NCCH3)][PF6] (Fig. 5) studied before in an independent 419 
experiment for related monocyclopentadienyliron(II)dppe derivatives [39] where the same 420 
electrochemical ligand exchange process was observed. In fact, for complexes 421 
[FeCp(dppe)(NC{SC4H2}nNO2)][PF6], the substitution of the thiophene ligands by the acetonitrile 422 
solvent was observed during the oxidative process in the electrochemical experiments. The reductive 423 
processes found at negative potentials were attributed to ligand-based processes occurring at the 424 
coordinated cyanoquinoline (L1 and L2) or pyrazine (L4) ligands, which became easier upon 425 
coordination. 426 
The electrochemical response of compounds 1, 2 and 4 in dichloromethane is slightly different. Fig. 6 427 
shows the cyclic voltammogram of complex [Fe(5-C5H5)(dppe)(3-cq)][PF6] 2 which typifies the 428 
electrochemical behavior of complexes 1 and 2 with the cyanoquinoline ligands. No substitution 429 
processes involving solvent molecules were observed and the redox behavior is characterized by the 430 
presence of a single quasi-reversible process (I) attributed to the FeII/FeIII redox pair in the range 0.84-431 
0.90 V at positive potentials and one or two irreversible reductive waves at negative range (II and III, 432 
see Fig. 6) derived from processes occurring at the coordinated cyanoquinoline ligands. Nevertheless, 433 
for complex 4 a distinct behavior was observed and only an irreversible metal centered oxidation at 0.66 434 
V was observed, indicating a complete decomposition process for the complex after iron(II) oxidation. 435 
Moreover, the instability in the electrochemical cell of compound 5 did not allow further studies. 436 
 437 
3.5.1. Atomic force microscopy 438 
Compounds 1e5 were incubated for 4 h at 37 °C in the molar relationship compound:DNA = 1:2. The 439 
images obtained by AFM are presented in Fig. 7. These images show that all the compounds modify the 440 
free DNA forms. In Fig. 7(a) the free pBR322 plasmid DNA shows the usual open and supercoiled 441 
forms. The image (b) shows the modifications caused by compound 1 after incubation with pBR322 442 
DNA clearly showing broken chains and a strong interaction of the complex on DNA. In image (c) it 443 
can be mainly observed an aggregation of the forms on the mica surface and modifications in the 444 
supercoling caused by interaction of compound 2 on pBR322 DNA. Compounds 3 and 4 produce similar 445 
effects on DNA (images (d) and (e), respectively): the number of supercoiled forms deposited on the 446 
mica has increased. Finally, image (f) reveals that complex 5 causes strong supercoling in some DNA 447 
forms and kinks in those forms that remain open. The authors have observed similar effects in 448 
compounds with planar ligands which probably intercalate on DNA [41]. 449 
 450 
3.5.2. Cytotoxicity of the iron complexes against HL-60 cells 451 
The cytotoxic effect of the iron complexes was examined on human leukemia cancer cells (HL-60) using 452 
the MTT assay, a colorimetric determination of cell viability during in vitro treatment with a drug. The 453 
assay, developed as an initial stage of drug screening, measures the amount of MTT reduction by 454 
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mitochondrial dehydrogenase and assumes that cell viability (corresponding to the reductive activity) is 455 
proportional to the production of purple formazan that is measured spectrophotometrically. A low IC50 456 
is desired and implies cytotoxicity or antiproliferation at low drug concentrations. All the new Fe(II) 457 
complexes were tested, together with cisplatin (CDDP) as a positive control. Cells were exposed to each 458 
compound continuously for a 24 h or a 72 h period of time and then assayed for growth using the MTT 459 
endpoint assay. Table 7 presents the IC50 values against HL-60 cells. The IC50 values at 24 h are lower 460 
than that for the reference drug, cisplatin. At 72 h, compounds 2 and 4 show higher IC50 values than 461 
cisplatin, although compounds 1, 3 and 5 present an excellent antiproliferative behavior with IC50 values 462 
lower than cisplatin forecasting interesting structureeactivity relationships. 463 
 464 
3.6. Quantification of apoptosis by Annexin V binding and flow cytometry 465 
We have also analyzed, by Annexin V-PI flow cytometry, whether complexes 1-5 are able to induce 466 
apoptosis in HL-60 cells after 24 h of incubation at equitoxic concentrations (IC50 values). Annexin V 467 
binds phosphatidyl serine residues, which are asymmetrically distributed towards the inner plasma 468 
membrane but migrate to the outer plasma membrane during apoptosis [33]. As it can be seen in Table 469 
8, complex 3 is able to induce apoptosis death in a 26.21%, close to that of cisplatin. Compounds 1, 4 470 
and 5, induce cell death by apoptosis in a lower percentage. Complex 2 presents only a discrete 471 






A new family of five half sandwich compounds derived from “FeII(5-C5H5)” bearing a coordinated 476 
nitrile ligand, which structure comprises one or two N-heteroaromatic rings, has been synthesized and 477 
successfully characterized. Spectroscopic evidence shows a strong p-backdonation involving the metal 478 
center. X-ray studies for two of these new compounds revealed crystallization in the monoclinic P21/c 479 
and monoclinic P21/n space groups.  480 
In a preliminary approach to evaluate the cytotoxic behavior of these new compounds against cancer 481 
cells, some studies were carried out involving human leukemia cancer cells (HL-60) by MTT assay. 482 
Also their interaction AFM images with pBR322 DNA plasmid show different behaviors that can be 483 
related with the NCL ligand. Indeed, IC50 values together with the apoptosis results show significant 484 
differences between the whole series of compounds. There are some main conclusions that can be drawn: 485 
i) compound 1, bearing the 2-quinolinecarbonitrile, presents the best cytotoxicity and its AFM image 486 
showed the most relevant modifications in pBR322 DNA; ii) structural difference in the position of the 487 
nitrile group in compounds 1 and 2 (ortho vs. meta) leads to a decrease on the cytotoxicity (4-fold); iii) 488 
comparison of results of compounds 2 and 3 (bearing in both cases the 3-quinolinecarbonitrile ligand) 489 
shows that the replacement of PF6 by CF3SO3 leads to a more cytotoxicity compound and the principal 490 
mechanism of death is changed from necrosis to apoptosis; iv) 2-pyrazinecarbonitrile (L3) leads to the 491 
less cytotoxic compound (4); and finally v) the introduction of a second nitrile group in L3 leads to a 3-492 
fold increase in the cytotoxic behavior (compound 5). The overall results show that after 24 h of 493 
incubation all the compounds are more cytotoxic than cisplatin. Thus, this is a potentially interesting 494 
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Legends to figures  578 
 579 
Scheme 1. Reaction scheme for the synthesis of the new Fe(II) complexes and the ligand structures 580 
numbered for NMR purposes 581 
 582 
Figure 1. Electronic spectra of [FeCp(dppe)(L)]þ (1e5) in dichloromethane solutions:––1; - - - - 2; ꞏꞏꞏꞏꞏ3; 583 
– – 4; – ꞏ – ꞏ 5. 584 
 585 
Figure 2. Electronic spectra of [Fe(5-C5H5)(dppe)(2-cq)][PF6] 1 in dichloromethane (ꞏꞏꞏꞏꞏꞏ) and 586 
dimethylsulfoxide (––) showing solvatochromism of the MLCT transition. 587 
 588 
Figure 3. ORTEP drawing of [Fe(5-C5H5)(dppe)(2-cq)][PF6] 1 with atomic numbering scheme. 589 
 590 
Figure 4. ORTEP drawing of [Fe(5-C5H5)(dppe) (3-cq)][CF3SO3] 3 with atomic numbering scheme. 591 
 592 
Figure 5. Cyclic voltammetry of complexes   [Fe(5-C5H5)(dppe) (2,3-dcpz)][PF6] 5 (––) and [Fe(5-593 
C5H5)(dppe)(NCMe)][PF6] (- - - - -) in acetonitrile (v = 200 mV/s). 594 
 595 
Figure 6. Cyclic voltammetry of complex [Fe(5-C5H5)(dppe)(3-cq)][PF6] 2 (––) and 3-cq ligand (- - 596 
- - -) in dichloromethane (v = 200 mV/s). 597 
 598 
Figure 7. AFM images of (a) plasmid pBR322 DNA and plasmid pBR322 DNA incubated with complex 599 
(b) [Fe(5-C5H5)(dppe)(2-cq)][PF6] 1, (c) [Fe(5-C5H5)(dppe)(3-cq)][PF6] 2, (d) [Fe(5-600 














Table 2. Optical spectra data for complexes [Fe(5-C5H5)(dppe)(L)]+ (1-5) in dichloromethane and 611 
























Table 5. Electrochemical data for complexes [Fe(5-C5H5)(dppe)L][PF6] (1 -5) in acetonitrile at scan 630 






Table 6. Electrochemical data for complexes [Fe(5-C5H5)(dppe)L][PF6] (1e6) in dichloromethane at 635 
















Table 8. Percentage of HL-60 cells in each state after treatment with complexes 1e5 at IC50 648 
concentration for 24 h of incubation. 649 
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